H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp (OMER) today and set a price target of $34. The company’s shares closed yesterday at $14.04.
Selvaraju said:
“Valuation methodology, risks and uncertainties. We currently ascribe a total firm value of roughly $2.3B to Omeros based on OMIDRIA ($820M) and OMS721 ($1.5B). This translates into a target of $34.00 per share, based on 68M fully-diluted shares outstanding as of end-2019. We assume the redemption of the senior convertible notes in full after one year, using proceeds from a follow-on offering of common stock in late 2019.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.1% and a 27.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is a Moderate Buy with an average price target of $33.
See today’s analyst top recommended stocks >>
Based on Omeros Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $39.47 million. In comparison, last year the company had a GAAP net loss of $7.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
Read More on OMER:
